查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1973877

人工智慧在癌症诊断市场分析及预测（至2035年）：按类型、产品类型、服务、技术、组件、应用、部署类型、最终用户、模组和功能划分

AI In Cancer Diagnostics Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Deployment, End User, Module, Functionality
出版日期: | 出版商: Global Insight Services | 英文 471 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计到2034年，癌症诊断领域的人工智慧（AI）市场规模将从2024年的2.681亿美元成长至23.601亿美元，复合年增长率约为24.3%。癌症诊断领域的人工智慧市场涵盖了利用人工智慧提高癌症检测和诊断准确性和效率的各种技术。该市场整合了机器学习演算法、影像识别和预测分析等技术，以辅助病理学家和放射科医生的工作。随着对早期癌症检测需求的不断增长，人工智慧驱动的解决方案对于减少诊断错误和改善患者预后至关重要。人工智慧技术的进步、医疗保健投资的增加以及对个人化医疗日益增长的关注，都推动了该市场的成长。

由于机器学习和成像技术的进步，人工智慧在癌症诊断领域的市场预计将显着成长。诊断成像领域是成长最快的细分市场，人工智慧驱动的成像工具能够提高早期检测率和诊断准确性。该领域主要由放射学和病理学领域的人工智慧应用主导，这些应用利用深度学习来增强诊断准确性。成长速度第二快的细分市场是基因组学。人工智慧分析复杂的基因数据正在革新个人化医疗。人工智慧驱动的基因组分析工具对于识别癌症生物标记和製定个人化治疗方案至关重要。人工智慧在切片检查分析中的应用也正在加速发展，能够更深入地了解肿瘤特征。此外，用于预测分析的人工智慧演算法对于预测预后和治疗结果也变得至关重要。科技公司和医疗服务提供者之间的合作促进了创新，进一步加速了人工智慧在癌症诊断领域的应用。法规结构的完善和人们对人工智慧潜力的认识不断提高，预计将推动未来市场扩张。

市场区隔
类型 影像学、基因组学、病理学、放射学、生物标记分析、临床决策支持
产品 软体、硬体、人工智慧平台、诊断设备
服务 咨询服务、整合服务、维护服务、培训和支持
科技 机器学习、深度学习、自然语言处理、电脑视觉
成分 人工智慧演算法、资料管理和使用者介面
应用 乳癌、肺癌、摄护腺癌、结肠癌
实施表格 云端部署、本地部署、混合部署
最终用户 医院、诊断检查室和研究实验室
模组 数据分析、预测建模和风险评估
功能 检测、预后和治疗计划

市场概况：

人工智慧癌症诊断市场正经历着市场份额的动态变化。技术进步和创新诊断解决方案的推出，导致定价策略竞争日益激烈。近期推出的产品主要致力于提高诊断准确率和缩短诊断时间。各公司正利用人工智慧改善患者预后并简化流程，进而推动全球医疗机构的快速采用。这一发展趋势正为癌症诊断带来变革性影响。人工智慧癌症诊断市场竞争异常激烈，IBM Watson Health 和 Google Health 等主要企业占据市场主导地位。这些公司正大力投资研发，以维持其竞争优势。监管的影响，尤其是在北美和欧洲，对塑造市场动态至关重要。遵守严格的标准能够确保产品的有效性和安全性，从而增强消费者的信心。在技​​术创新和有利的法规环境的推动下，该市场正呈现出成长的迹象。

主要趋势和驱动因素：

由于技术进步和癌症发病率的上升，人工智慧在癌症诊断领域的市场正经历强劲成长。关键趋势包括将人工智慧与成像技术相结合，以提高癌症检测的准确性和速度。机器学习演算法的进步，例如能够分析复杂资料集的演算法，正在推动诊断准确性的提高和个人化治疗方案的发展。对早期、精准癌症诊断日益增长的需求，正在推动人工智慧解决方案的普及。医疗机构越来越多地利用人工智慧来减少诊断错误并改善患者预后。大型资料集的日益丰富使得训练更先进的人工智慧模型成为可能，进一步促进了市场成长。此外，科技公司与医疗机构之间的合作正在推动人工智慧在癌症诊断应用领域的创新。在医疗基础设施不断完善的发展中地区，新的机会正在涌现。能够提供扩充性且经济高效的人工智慧解决方案的公司，将占据有利的市场份额。此外，监管机构对人工智慧驱动的诊断工具的支持，也促进了这些工具的普及，从而推动了市场的持续扩张。

限制与挑战：

人工智慧在癌症诊断领域的市场面临许多重大限制和挑战。最重要的是，监管合规和核准流程依然严格且耗时，往往阻碍了市场准入和创新。此外，将人工智慧系统整合到现有医疗基础设施中也存在技术和营运方面的挑战，需要大量的投资和培训。资料隐私和安全问题同样不容忽视，因为敏感的病患资讯必须受到保护，免于外洩和滥用。此外，高品质、带有标註的资料集严重短缺，而这些资料集对于训练人工智慧演算法至关重要，这也限制了诊断工具的有效性和准确性。最后，来自医疗专业人员的抵触情绪也是一个挑战。他们可能对人工智慧的可靠性持怀疑态度，或担心失去工作。总而言之，这些挑战阻碍了人工智慧技术在癌症诊断领域的快速普及和发展，需要製定策略性的解决方案来克服这些挑战。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 影像
    • 基因组学
    • 病理
    • 放射医学
    • 生物标记分析
    • 临床决策支持
  • 市场规模及预测：依产品划分
    • 软体
    • 硬体
    • 人工智慧平台
    • 诊断设备
  • 市场规模及预测：依服务划分
    • 咨询服务
    • 整合服务
    • 维护服务
    • 培训和支持
  • 市场规模及预测：依技术划分
    • 机器学习
    • 深度学习
    • 自然语言处理
    • 电脑视觉
  • 市场规模及预测：依组件划分
    • 人工智慧演算法
    • 资料管理
    • 使用者介面
  • 市场规模及预测：依应用领域划分
    • 乳癌
    • 肺癌
    • 摄护腺癌
    • 大肠直肠癌
  • 市场规模及预测：依发展状况
    • 基于云端的
    • 本地部署
    • 杂交种
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊断检查室
    • 研究所
  • 按模组分類的市场规模和预测
    • 数据分析
    • 预测建模
    • 风险评估
  • 市场规模及预测：依功能划分
    • 侦测
    • 前景
    • 治疗计划

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Tempus
  • PathAI
  • Zebra Medical Vision
  • Freenome
  • CureMetrix
  • Ibex Medical Analytics
  • Deep Lens
  • Proscia
  • Oncora Medical
  • Enlitic
  • Owkin
  • Miramus
  • Lunit
  • Qure.ai
  • Aiforia
  • Kheiron Medical
  • Huron Digital Pathology
  • Viz.ai
  • Koios Medical
  • Aidence

第九章：关于我们

简介目录
Product Code: GIS33042

AI In Cancer Diagnostics Market is anticipated to expand from $268.1 million in 2024 to $2,360.1 million by 2034, growing at a CAGR of approximately 24.3%. The AI in Cancer Diagnostics Market encompasses technologies utilizing artificial intelligence to enhance the accuracy and efficiency of cancer detection and diagnosis. This market integrates machine learning algorithms, image recognition, and predictive analytics to aid pathologists and radiologists. As demand for early cancer detection rises, AI-driven solutions are pivotal in reducing diagnostic errors and improving patient outcomes. The market is poised for growth, driven by advancements in AI technology, increasing healthcare investments, and a growing emphasis on personalized medicine.

The AI in Cancer Diagnostics Market is poised for significant growth, driven by advancements in machine learning and imaging technologies. The imaging segment is the top-performing sub-segment, with AI-powered imaging tools enhancing early detection and diagnostic accuracy. Within this segment, radiology and pathology AI applications are leading, leveraging deep learning to improve diagnostic precision. The second highest performing sub-segment is the genomics segment, where AI is revolutionizing personalized medicine by analyzing complex genetic data. AI-driven genomic tools are crucial in identifying cancer biomarkers and tailoring treatment plans. The integration of AI in biopsy analysis is also gaining momentum, offering enhanced insights into tumor characteristics. Moreover, AI algorithms for predictive analytics are becoming indispensable, aiding in prognosis and treatment outcome predictions. The adoption of AI in cancer diagnostics is further propelled by collaborations between tech companies and healthcare providers, fostering innovation. Enhanced regulatory frameworks and increasing awareness of AI's potential are expected to drive future market expansion.

Market Segmentation
TypeImaging, Genomics, Pathology, Radiology, Biomarker Analysis, Clinical Decision Support
ProductSoftware, Hardware, AI Platforms, Diagnostic Devices
ServicesConsulting Services, Integration Services, Maintenance Services, Training and Support
TechnologyMachine Learning, Deep Learning, Natural Language Processing, Computer Vision
ComponentAI Algorithms, Data Management, User Interface
ApplicationBreast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer
DeploymentCloud-Based, On-Premises, Hybrid
End UserHospitals, Diagnostic Laboratories, Research Institutes
ModuleData Analysis, Predictive Modelling, Risk Assessment
FunctionalityDetection, Prognosis, Treatment Planning

Market Snapshot:

The AI in Cancer Diagnostics Market is witnessing a dynamic shift in market share. Pricing strategies are increasingly competitive, driven by technological advancements and the introduction of innovative diagnostic solutions. Recent product launches have demonstrated a focus on enhancing accuracy and reducing diagnostic time. Companies are leveraging AI to improve patient outcomes and streamline processes, which is fostering rapid adoption across healthcare institutions globally. This evolution is setting the stage for a transformative impact on cancer diagnostics. Competition in the AI in Cancer Diagnostics Market is intensifying, with key players like IBM Watson Health and Google Health leading the charge. These companies are investing heavily in research and development to maintain a competitive edge. Regulatory influences, particularly in North America and Europe, are crucial in shaping market dynamics. Compliance with stringent standards ensures product efficacy and safety, thereby boosting consumer trust. The market is poised for growth, driven by technological innovations and favorable regulatory environments.

Geographical Overview:

The AI in cancer diagnostics market is poised for substantial growth across diverse regions. North America leads the charge, propelled by its advanced healthcare infrastructure and robust AI research initiatives. The region's focus on early cancer detection and personalized medicine further augments this growth. Europe follows closely, with significant investments in AI-driven healthcare solutions. The continent's emphasis on regulatory frameworks ensures the safe integration of AI technologies in diagnostics. Asia Pacific is emerging as a vital growth pocket, driven by increasing cancer prevalence and technological advancements. Countries like China and India are at the forefront, investing heavily in AI research and healthcare innovation. These nations are poised to revolutionize cancer diagnostics with their rapid adoption of AI technologies. Meanwhile, Latin America and the Middle East & Africa are gradually recognizing the potential of AI in healthcare. These regions are beginning to invest in AI infrastructure, promising future growth in cancer diagnostics.

Key Trends and Drivers:

The AI in Cancer Diagnostics Market is experiencing robust growth due to technological advancements and increasing cancer prevalence. Key trends include the integration of AI with imaging technologies, enhancing the accuracy and speed of cancer detection. Machine learning algorithms are being developed to analyze complex datasets, improving diagnostic precision and personalized treatment planning. The demand for early and accurate cancer diagnosis is driving the adoption of AI solutions. Healthcare providers are increasingly leveraging AI to reduce diagnostic errors and improve patient outcomes. The growing availability of large datasets is enabling the training of more sophisticated AI models, further propelling market growth. Additionally, collaborations between technology companies and healthcare institutions are fostering innovation in AI applications for cancer diagnostics. Opportunities are emerging in developing regions where healthcare infrastructure is expanding. Companies that offer scalable and cost-effective AI solutions are well-positioned to capture market share. Furthermore, regulatory support for AI-driven diagnostic tools is enhancing their adoption, promising sustained market expansion.

Restraints and Challenges:

The AI in Cancer Diagnostics Market is confronted with several significant restraints and challenges. Foremost among these is the regulatory compliance and approval process, which remains stringent and time-consuming, often delaying market entry and innovation. Additionally, the integration of AI systems into existing healthcare infrastructure presents technical and operational difficulties, requiring substantial investment and training. Data privacy and security concerns also pose critical challenges, as sensitive patient information must be safeguarded against breaches and misuse. Furthermore, there is a notable scarcity of high-quality, annotated datasets necessary for training AI algorithms, which limits the efficacy and accuracy of diagnostic tools. Lastly, the market faces resistance from healthcare professionals who may be skeptical of AI's reliability and fear potential job displacement. These challenges collectively impede the rapid adoption and growth of AI technologies in cancer diagnostics, necessitating strategic solutions to overcome them.

Key Players:

Tempus, PathAI, Zebra Medical Vision, Freenome, CureMetrix, Ibex Medical Analytics, Deep Lens, Proscia, Oncora Medical, Enlitic, Owkin, Miramus, Lunit, Qure.ai, Aiforia, Kheiron Medical, Huron Digital Pathology, Viz.ai, Koios Medical, Aidence

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by Deployment
  • 2.8 Key Market Highlights by End User
  • 2.9 Key Market Highlights by Module
  • 2.10 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Imaging
    • 4.1.2 Genomics
    • 4.1.3 Pathology
    • 4.1.4 Radiology
    • 4.1.5 Biomarker Analysis
    • 4.1.6 Clinical Decision Support
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Software
    • 4.2.2 Hardware
    • 4.2.3 AI Platforms
    • 4.2.4 Diagnostic Devices
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consulting Services
    • 4.3.2 Integration Services
    • 4.3.3 Maintenance Services
    • 4.3.4 Training and Support
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Machine Learning
    • 4.4.2 Deep Learning
    • 4.4.3 Natural Language Processing
    • 4.4.4 Computer Vision
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 AI Algorithms
    • 4.5.2 Data Management
    • 4.5.3 User Interface
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Breast Cancer
    • 4.6.2 Lung Cancer
    • 4.6.3 Prostate Cancer
    • 4.6.4 Colorectal Cancer
  • 4.7 Market Size & Forecast by Deployment (2020-2035)
    • 4.7.1 Cloud-Based
    • 4.7.2 On-Premises
    • 4.7.3 Hybrid
  • 4.8 Market Size & Forecast by End User (2020-2035)
    • 4.8.1 Hospitals
    • 4.8.2 Diagnostic Laboratories
    • 4.8.3 Research Institutes
  • 4.9 Market Size & Forecast by Module (2020-2035)
    • 4.9.1 Data Analysis
    • 4.9.2 Predictive Modelling
    • 4.9.3 Risk Assessment
  • 4.10 Market Size & Forecast by Functionality (2020-2035)
    • 4.10.1 Detection
    • 4.10.2 Prognosis
    • 4.10.3 Treatment Planning

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 Deployment
      • 5.2.1.8 End User
      • 5.2.1.9 Module
      • 5.2.1.10 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 Deployment
      • 5.2.2.8 End User
      • 5.2.2.9 Module
      • 5.2.2.10 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 Deployment
      • 5.2.3.8 End User
      • 5.2.3.9 Module
      • 5.2.3.10 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 Deployment
      • 5.3.1.8 End User
      • 5.3.1.9 Module
      • 5.3.1.10 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 Deployment
      • 5.3.2.8 End User
      • 5.3.2.9 Module
      • 5.3.2.10 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 Deployment
      • 5.3.3.8 End User
      • 5.3.3.9 Module
      • 5.3.3.10 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 Deployment
      • 5.4.1.8 End User
      • 5.4.1.9 Module
      • 5.4.1.10 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 Deployment
      • 5.4.2.8 End User
      • 5.4.2.9 Module
      • 5.4.2.10 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 Deployment
      • 5.4.3.8 End User
      • 5.4.3.9 Module
      • 5.4.3.10 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 Deployment
      • 5.4.4.8 End User
      • 5.4.4.9 Module
      • 5.4.4.10 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 Deployment
      • 5.4.5.8 End User
      • 5.4.5.9 Module
      • 5.4.5.10 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 Deployment
      • 5.4.6.8 End User
      • 5.4.6.9 Module
      • 5.4.6.10 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 Deployment
      • 5.4.7.8 End User
      • 5.4.7.9 Module
      • 5.4.7.10 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 Deployment
      • 5.5.1.8 End User
      • 5.5.1.9 Module
      • 5.5.1.10 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 Deployment
      • 5.5.2.8 End User
      • 5.5.2.9 Module
      • 5.5.2.10 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 Deployment
      • 5.5.3.8 End User
      • 5.5.3.9 Module
      • 5.5.3.10 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 Deployment
      • 5.5.4.8 End User
      • 5.5.4.9 Module
      • 5.5.4.10 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 Deployment
      • 5.5.5.8 End User
      • 5.5.5.9 Module
      • 5.5.5.10 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 Deployment
      • 5.5.6.8 End User
      • 5.5.6.9 Module
      • 5.5.6.10 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 Deployment
      • 5.6.1.8 End User
      • 5.6.1.9 Module
      • 5.6.1.10 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 Deployment
      • 5.6.2.8 End User
      • 5.6.2.9 Module
      • 5.6.2.10 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 Deployment
      • 5.6.3.8 End User
      • 5.6.3.9 Module
      • 5.6.3.10 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 Deployment
      • 5.6.4.8 End User
      • 5.6.4.9 Module
      • 5.6.4.10 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 Deployment
      • 5.6.5.8 End User
      • 5.6.5.9 Module
      • 5.6.5.10 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Tempus
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 PathAI
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Zebra Medical Vision
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Freenome
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 CureMetrix
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Ibex Medical Analytics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Deep Lens
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Proscia
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Oncora Medical
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Enlitic
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Owkin
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Miramus
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Lunit
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Qure.ai
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Aiforia
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Kheiron Medical
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Huron Digital Pathology
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Viz.ai
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Koios Medical
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Aidence
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us